This new eBook from The Center for Biosimilars

® tells the compelling story of how biosimilar development and uptake have been affected by COVID-19. Read it and find out how biosimilars may emerge from the pandemic as a more powerful, more valuable force in lower-cost medicine.

The Disruptor: How Coronavirus Disease 2019 (COVID-19) Has Affected the Development and Uptake of Biosimilars

Are you ready for the upcoming 2020 transition of insulins and other therapeutic proteins to US regulation as biologics and biosimilars? Find out what you need to know about the regulatory change with a new ebook from The Center for Biosimilars®.

Preparing for the 2020 Regulatory Transition of Insulin and Other Therapeutic Proteins

Strategies for Successful Adoption of Biosimilars in Practice: Takeaways From the West Cancer Center Experience

Biosimilars 101:  Practice Concerns, Market Acceptance, and the Biosimilars Pipeline

Pfizer Global Biosimilars Commercial Lead, Roman Irsiegler, gives his thoughts on why a sustainable biosimilars market is critical for the healthcare industry, and what stakeholders can do to achieve it.

Biosimilar Resources